• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Providers

Latest News

The OCEANIC-STROKE subgroup analysis findings, in tandem with the main results presented at ISC 2026, suggest that targeting factor XIa could be a safe way to intensify antithrombotic therapy following noncardioembolic stroke, regardless of underlying etiology. | Image credit: jolygon - stock.adobe.com
Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

February 6th 2026

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

GLP-1 agonists remain largely untested in this at-risk patient population and warrant further research, experts said. | Image credit: mingnimit - stock.adobe.com
How Do GLP-1 Agonists Fit Into Stroke Care?

February 6th 2026

Asundexian with standard antiplatelet therapy helped reduce the chances of a recurrent stroke without increasing the risk of bleeding, according to the OCEANIC-STROKE trial. | Image credit: Studio Multiverse - stock.adobe.com
Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial

February 5th 2026

International Stroke Conference 2026 research emphasizes that not only is the stroke treatment landscape changing, but so is stroke epidemiology research. | Image credit: samunella - stock.adobe.com
Underrecognized Stroke Risk Factors in Focus at ISC 2026

February 5th 2026

Many solutions to improve disparities in stroke care come down to appropriate tailoring for the target system and community. | Image credit: BJP7images - stock.adobe.com
Closing Gaps in Stroke Care Starts With Defining the US Health Care Safety Net

February 5th 2026

More News

© 2026 MJH Life Sciences
AJMC®
All rights reserved.